Status:
COMPLETED
A Study of Duration of Maintained Efficacy in Rheumatoid Arthritis (RA) Patients Off Treatment With MRA(a Development Code of Tocilizumab, an Anti IL-6 Receptor Monoclonal Antibody.)
Lead Sponsor:
Chugai Pharmaceutical
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
20+ years
Brief Summary
A 52-week follow up study to investigate the duration of maintenance of efficacy in patients with RA and achieved low disease activity in clinical trials of MRA and stopped the treatment
Eligibility Criteria
Inclusion
- Patients who achieved DAS28 of \< 3.2 at the last observation and at least one time point among the two previous assessment time points in a previous studies.
Exclusion
- Patients who receive DMARDs or immunosuppressants between the last observation in a previous studies and the first observation in this study
Key Trial Info
Start Date :
April 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2010
Estimated Enrollment :
189 Patients enrolled
Trial Details
Trial ID
NCT00661284
Start Date
April 1 2008
End Date
May 1 2010
Last Update
August 2 2012
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Chugoku region
Chugoku, Japan
2
Kanto region
Kanto, Japan
3
Kyushu region
Kyushu, Japan
4
Sikoku region
Sikoku, Japan